@misc{oai:repo.qst.go.jp:00073344,
 author = {Yoshinaga, Keiichiro and 吉永 恵一郎},
 month = {Nov},
 note = {Abstract
With increasing aging population, the numbers of cardiovascular disease especially heart failure (HF) has been increasing and management of HF patients are emerging topic in clinical setting. 
Cardiac metabolism appears to change in HF patients. The main resource of cardiac metabolism shifts from fatty acid metabolism to glucose metabolism. This metabolic shifts typically appears in HF due to coronary artery disease (CAD). 18F-FDG PET has been approved to detect dysfunctional but viable myocardium in Japan and US. 18F-FDG PET plays an important role for making indication for coronary artery revascularization. 
HF is characterized by an energy-depleted states. Increasing afterload increases the metabolic demand. HF treatments reduce the metabolic demand usually improve the patient outcomes such as beta-blocker therapy. Using PET, it is possible to non-invasively estimate myocardial oxygen consumption as oxidative metabolism. Our group have applied this approach to evaluate several new HF treatments such as HF with sleep disorder and surgical left ventricular reconstruction.
Right ventricular (RV) ion and attenuated RV metabolism played an important role in developing RV failure in patients with pulmonary hypertension (PH). Recent treatment developments of PH require useful therapeutic markers in clinical settings. PET metabolic imaging using C-11 acetate and 11C palmitate would be useful markers for the treatment monitoring. 
This talk would focus on the LV and RV metabolic imaging using cardiac PET and their contributions to the treatment strategy of HF., 第58回日本核医学会学術総会},
 title = {Role of cardiac metabolic imaging for therapeutic strategies for heart failure},
 year = {2018}
}